Harry  Fisch net worth and biography

Harry Fisch Biography and Net Worth

Director of Veru
Harry Fisch, M.D., F.A.C.S. is the Founder, Vice Chairman of the Board, and Chief Corporate Officer of Veru Inc. and has served as a director of the Company since October 2016. Dr. Fisch was the co-founder of Aspen Park and served as the Chairman of the Board and Chief Scientific Officer of Aspen Park from July 2014 to October 2016. From 1994 to 2016, Dr. Fisch served as the Chief Executive Officer and President of Millennium Sciences, Inc. Dr. Fisch has also had numerous academic and clinical appointments including Clinical Professor of Urology and Reproductive Medicine at Weill College of Medicine, Cornell University from 2009 to current, Director of the Male Reproductive Center at Albert Einstein College of Medicine/Montefiore Medical Center from 1998 to 1999 and Professor of Clinical Urology at Columbia University, College of Physicians and Surgeons from 1999 to 2009. From 2014 to 2015, Dr. Fisch hosted The Dr. Harry Fisch Show on Men’s Health on Howard Stern’s SiriusXM radio channel 101. Dr. Fisch is a Board Certified Urologist and a Fellow of the American College of Surgeons. Dr. Fisch holds a B.A. in Chemistry from the State University of New York at Binghamton, an M.D. from Mount Sinai School of Medicine, New York, and performed his surgical and urologic training at Albert Einstein College of Medicine/Montefiore Medical Center.

How old is Harry Fisch?

Dr. Fisch is currently 65 years old. There are 4 older executives and no younger executives at Veru. Learn More on Harry Fisch's age.

How do I contact Harry Fisch?

The corporate mailing address for Dr. Fisch and other Veru executives is 48 NW 25th Street Suite 102, Miami FL, 33127. Veru can also be reached via phone at (305) 509-6897 and via email at [email protected]. Learn More on Harry Fisch's contact information.

Has Harry Fisch been buying or selling shares of Veru?

Harry Fisch has not been actively trading shares of Veru during the last ninety days. Most recently, Harry Fisch sold 100,000 shares of the business's stock in a transaction on Wednesday, June 16th. The shares were sold at an average price of $8.35, for a transaction totalling $835,000.00. Learn More on Harry Fisch's trading history.

Who are Veru's active insiders?

Veru's insider roster includes Harry Fisch (Director), and Lucy Lu (Director). Learn More on Veru's active insiders.

Harry Fisch Insider Trading History at Veru

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/16/2021Sell100,000$8.35$835,000.00View SEC Filing Icon  
8/26/2020Buy5,000$2.76$13,800.00View SEC Filing Icon  
2/21/2020Buy1,000$4.34$4,340.00View SEC Filing Icon  
9/3/2019Buy10,000$1.93$19,300.00View SEC Filing Icon  
8/29/2019Buy7,000$1.92$13,440.00View SEC Filing Icon  
3/15/2019Buy3,000$1.47$4,410.00View SEC Filing Icon  
3/13/2019Buy3,500$1.47$5,145.00View SEC Filing Icon  
3/5/2019Buy3,500$1.47$5,145.00View SEC Filing Icon  
2/26/2019Buy5,000$1.27$6,350.00View SEC Filing Icon  
2/21/2019Buy5,000$1.35$6,750.00View SEC Filing Icon  
2/19/2019Buy5,000$1.36$6,800.00View SEC Filing Icon  
2/15/2019Buy13,681$1.36$18,606.16View SEC Filing Icon  
12/18/2018Buy30,000$1.42$42,600.00View SEC Filing Icon  
3/16/2018Buy5,000$1.96$9,800.00View SEC Filing Icon  
3/14/2018Buy10,000$1.87$18,700.00View SEC Filing Icon  
3/12/2018Buy10,000$1.80$18,000.00View SEC Filing Icon  
3/9/2018Buy10,000$1.88$18,800.00View SEC Filing Icon  
3/7/2018Buy24,000$1.62$38,880.00View SEC Filing Icon  
9/13/2017Buy34,250$1.51$51,717.50View SEC Filing Icon  
5/30/2017Buy12,000$1.27$15,240.00View SEC Filing Icon  
5/24/2017Buy10,000$1.10$11,000.00View SEC Filing Icon  
5/22/2017Buy24,750$1.02$25,245.00View SEC Filing Icon  
See Full Table

Harry Fisch Buying and Selling Activity at Veru

This chart shows Harry Fisch's buying and selling at Veru by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Veru Company Overview

Veru logo
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $1.42
Low: $1.00
High: $1.43

50 Day Range

MA: $0.72
Low: $0.38
High: $1.79

2 Week Range

Now: $1.42
Low: $0.36
High: $1.92

Volume

7,015,405 shs

Average Volume

2,389,558 shs

Market Capitalization

$207.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A